TW565455B - Quinapril-containing pharmaceutical composition comprising magnesium oxide, tablet comprising the same and process for stabilizing a quinapril drug - Google Patents
Quinapril-containing pharmaceutical composition comprising magnesium oxide, tablet comprising the same and process for stabilizing a quinapril drug Download PDFInfo
- Publication number
- TW565455B TW565455B TW088108107A TW88108107A TW565455B TW 565455 B TW565455 B TW 565455B TW 088108107 A TW088108107 A TW 088108107A TW 88108107 A TW88108107 A TW 88108107A TW 565455 B TW565455 B TW 565455B
- Authority
- TW
- Taiwan
- Prior art keywords
- quinapril
- magnesium oxide
- chinese
- composition
- hydrolysis
- Prior art date
Links
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 title claims abstract description 128
- 239000000395 magnesium oxide Substances 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 11
- 230000008569 process Effects 0.000 title claims abstract description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 title claims abstract 9
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 title claims description 30
- 229960001455 quinapril Drugs 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 claims abstract description 106
- 230000007062 hydrolysis Effects 0.000 claims abstract description 31
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 31
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 24
- 239000003381 stabilizer Substances 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 238000002845 discoloration Methods 0.000 claims abstract description 10
- 238000009472 formulation Methods 0.000 claims description 40
- 239000003826 tablet Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000005426 pharmaceutical component Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- VQCBHWLJZDBHOS-UHFFFAOYSA-N erbium(iii) oxide Chemical compound O=[Er]O[Er]=O VQCBHWLJZDBHOS-UHFFFAOYSA-N 0.000 claims 2
- 241000220317 Rosa Species 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 abstract description 32
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract description 32
- 235000012245 magnesium oxide Nutrition 0.000 description 59
- 238000005469 granulation Methods 0.000 description 15
- 230000003179 granulation Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 14
- 239000000347 magnesium hydroxide Substances 0.000 description 14
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000005550 wet granulation Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- -1 Piramine Chemical compound 0.000 description 9
- 108010010803 Gelatin Proteins 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 8
- 239000001095 magnesium carbonate Substances 0.000 description 8
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 8
- 235000014380 magnesium carbonate Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 229940030606 diuretics Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960003042 quinapril hydrochloride Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000979 retarding effect Effects 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)-3,4-dihydroxy-2h-furan-5-one Chemical compound OCC(O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FMDLISAHAFBTRH-UHFFFAOYSA-J C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Re+4].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-] Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Re+4].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[O-] FMDLISAHAFBTRH-UHFFFAOYSA-J 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101150029544 Crem gene Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 101100230601 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HBT1 gene Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940077422 accupril Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical class O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- XNEYCQMMVLAXTN-UHFFFAOYSA-N carbonic acid;magnesium Chemical compound [Mg].OC(O)=O XNEYCQMMVLAXTN-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960003871 codeine sulfate Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229950009810 indolapril Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
565455 ⑴ X <rv^x n4,^AviJ^KK i£«&iCS^V«*^V^ ί ^ ^y% S > rf^^vrftw^ -x~ ¢.^ «· —f*·、〆*·及 *、m 汾·· r、*_^*· f w 你、j 必、夂、i * 《-t a < 如(* a · · t *·办灿* 々-a、、 P*a、( (發明說明應敘明:發明所屬之技術領域、先前技術、内容、實施方式及圖式簡單說明) 發明範疇 本發明係關於經由氧化鎂之存在所安定之含有ACE抑 制劑之組合物。當在基本上由作為安定劑之氧化鎂所組成 之藥物組合物中予以製備時,較佳,保護A C E抑制劑,4 那普利(quinapril)不會有某種形式的降解。在製造含有 A CE抑制劑之組合物期間,氧化鎂的存在亦對良好之處理 條件有用,尤其經由溼成粒之處理。 發明背景 某些ACE(血管緊縮素轉化酶)抑制劑(其作為抗高血壓 劑有效)易於感受某種型式的降解。特別,奎那普利機結 構上有關之藥物可經由下列(1)至(3)項而降解:(1)經由内 部親核侵襲而形成經取代之二酮基哌嗪之環化,(2)側鏈 酯基之水解及(3)氧化而形成具有時常不需要之著色的產 物。 美國專利案第4,743,450中揭示··含有上文中所討論之 該型的ACE抑制劑之安定組合物可使用某些添加劑作為 安定劑而製成。特別,此專利案中揭示:充作含有ACE 抑制劑之調配物的安定劑之周期表中第I族與第Π族金屬 的無機鹽類易感受某種型式的降解。教導碳酸鎂是較佳安 定劑。 一種ACE抑制劑,喹那普利商業上以ACCUPRIL®商標 名字而出售,並採用碳酸氫氧化鎂在其配方中。碳酸氫氧 化鎂含有大概40%至42%氧化鎂。 565455 (2) 雖然竣酸氫氧化鎂充作4那普利之有效安定劑,但是其 使用於藥物調配物中顯現某些缺點。碳酸氫氧化鎂是白 色,龐大粉末,因為其不良壓縮性,模塑性和流動性,難 以將它調配成片劑。當組合物使用溼成粒方法予以製造 時,加重經由使用碳酸氫氧化鎂調配含有ACE抑制劑之組 合物所遇到之困難。 經由溼成粒而製備片劑之顆粒是最古老方法且仍然最 廣泛使用。在乾燥前,壓實變成重要之過程,為了所有實 用目的,溼成粒是可供利用之唯一方法。然而,它是費事 的,涉及甚多之物料處理以及數項處理步驟而因此之故, 它是昂貴。就大體而論,該技術包括只不過以如此數量和 方式,摻合粒狀流體入經混合之粉狀片劑成份(包括至少 某些成片之助劑)中以使轉化彼等成為均勻,潮溼,内聚, 非糊狀物料,然後通常,經由強制該物料通過一只篩而形 成為具有良好均勻大小的溼顆粒。其後,將溼顆粒乾燥並 再篩選而使凝聚物破裂,最後與其他成片之助劑摻合以便 因此達到預備製成片劑之成粒。 應述及者:在溼成粒時,除去活性物質以外,片劑成份 亦習見包括其他藥理學上惰性物料,當然,成片助劑也許 亦包括膨脹劑。在將成粒之流體摻合入其中前,可將某些 此類成片助劑包括入經混合之粉狀成份中,在已形成顆粒 後及將顆粒通至成片機前,同時可將另外之成片助劑施加 至顆粒的表面上及在其中間。 當將化合物像碳酸氫氧化鎂與ACE抑制劑像喹那普利 (3) (3)565455 口時,浚成粒方法的勞力和成本如此特性係普遍。 ,處理灭酸氫氧化鎂時,製造商已經驗數種限制速率之 :驟·由於碳酸氫氧化鎂摻合物的較低密度的限制之分批 ^小;,15分鐘或較長之成粒時間;當使用不同批的碳酸氫 虱化鎂時,15至37分鐘成粒時間之可變性;須要大量的水 而獲彳于成粒終點及以2 3至2 9 %範圍内之起始乾燥指生 基準,% * 貝天為 滑在性長乾燥時間(乾燥損失或,,LOD”是使用熱之 欠岛"、彳走4驗,目的在測定··多少水或溶劑在一種產物 中),及流動性之限制。 因為來源關係碳酸氫氧化鎂對於製造商亦是一個難題。 應了解者:如果能改良含有ACE抑制劑之配方的澄成粒 處理條件而不損失化合物,像碳酸氫氧化鎂的安定效果, 則可能是該項技藝之一大改進。 發明總結 現已發現:上文中所討論之該型的含有ACE抑制劑之安 足、’且口物可使用氧化鎂作為主要環化安定劑而製造。在一 個具體實施例中,藥物組合物之製備係經由將ACE抑制 劑’喹那普利HC1與基本上由氧化鎂所組成之安定劑聯 "使用氧化鎂不僅將ACE抑制劑的環化降解減至最小而 艮了經由溼成粒技術,調配ACE抑制劑入藥物組合物 中在較佳具體實施例中,藥物組合物之製備係經由將 抑制劑不僅與基本上由氧化鎂所組成之安定劑聯 口,而且與將ACE抑制劑的水解減至最少之學劑聯合,例 糖頒,利尿劑,磷酸二鈣或對於A c E抑制劑具有將水解 (4)
減至最少之效果的一般所熟知之填料。在更佳者中,藥物 組合 物之製備係經由聯合5.8wt°/。之氧化鎂,5.8wt%之喹那 普利HC1連同包括88.3wt%之乳糖而產生一種組合物,它 耐氧化,水解並在60 °C下耐環化降解歷10天。 在另外具體實施例中,揭示使用氧化鎂而製備經安定, 含有ACE抑制劑之組合物的方法。該方法包括下列步驟: 使ACE抑制劑與適當數量的基本上由氧化鎂及一種或多 種將水解減至最少之劑,例如糖類所組成之安定 將水解減至最少。在較佳具體實施例中,該方法包括下列 步驟使喹那普利HC1與適當數量的基本上由氧化鎂和一 或數種糖碩所組成之安定劑接觸而形成一種混合物;及 使該混合物歷經溼成粒處理。 本發明的*、 、、口物較不含安定之添加劑的組合物具有數 、^王要,事貫上’將經包含在其中之活性成份或藥 物保護免於埙a i & & ^ ^ 、 和水解。另外,將褪色減至最少或完全消 除,當凋配此# Μ Δ r 古卩去八旅 居勺 抑制劑並容許靜置歷甚久時間時, 有時合發+ & 1 調配物,其可,取因此,可產生—種安定,片狀喹那普利 了經歷不可檢測之氧化褪色。 除入具有較大之儲存安定性以外,致使本發明之,a 更適合供使用《藥物冑"。 《调配物 由於碳酸g t
之#點1 虱化鎂存在之事實,本發明調配物且有U (優點,消降7 # 士甘 〜丹有另外 借H 、斤有其固有之缺點。經由溼成粒技& ^ 備具有虱化鍰, \紅技術,製 作為王要t疋劑之含有ACE抑制劑之组入 565455 (5) 物導致改良之處理。降低成本和勞之改進包括(但並非受 限為):由於氧化鎂調配物的高密度而增加分批大小;成 粒時間為4.5至5分鐘或更短;當使用不同批的氧化鎂時, 減少成粒時間之變更性/〇 · 5至1分鐘間;減少獲得成粒終 點之水的數量及以5%至8%範圍内之起始乾燥損失(LOD) 數值為基準而縮短乾燥時間以及改良了流動性。
本發明的此等及其他優點自研究本發明之下列敘述將 顯然可見。 發明之詳述 本發明研究: I. 一種藥物組合物,其含有: (a) 有效數量的藥物組份,其中包含ACE抑制劑,它易 於感受環化,水解及/或褪色,及
(b) 有效數量的氧化鎂和適合阻滯環化,水解及/或褪色 之將水解減至最少劑,其中氧化鎂是該組合物的主要環化 安定劑組份。 II. 用於安定A C E抑制劑藥物之方法,此方法包括下列步 驟:使藥物與: (a)有效數量的氧化鎂和適合阻滯環化,水解及/或褪色 之將水解減至最少劑接觸,其中氧化鎂是該組合物的主要 環化安定劑組份。 III. 製造藥物劑量形式之方法,此方法包括將適當數量的(a) 與(b)項包括入調配物中的步驟: (a)—種ACE抑制劑,及 -10- 565455 ⑹ (b)氧化鎂和劑量形式的阻滯環化,水解及/或褪色之將 水解減至最少劑,氧化鎂充作該劑量形式的主要環化安定 劑組份。 依照本發明所造成和所使用之組合物及方法較佳亦含 有不干涉安定之添加劑功能之一種或多種物質。通常,潤 滑劑例如硬脂酸鍰,氫化植物油和滑石,黏石劑例如明膠 及/或粉碎劑例如聚乙烯吡咯烷酮均適合。
藥物組份 本發明的組合物含有至少一種ACE抑制劑及視情況選 用之一種或多種藥物或有益之物質。可使用於本發明中之 A C E抑制劑是具有抗高血壓性質之一組的著名化合物任 一者。 較佳一組之化合物包括具有下列通式之化合物:
其中A是不存在,一個稠合5,6或7節之環脂族環或稠 合之苯環,其係未經取代或經由具有1至4個碳原子之1或2 烷氧基所取代;η是0或1,而R是氫或具有1至5個碳原子 之烷基。較佳者,Α係不存在,一個稠合5或6節環脂族環 或稠合之苯環,其係未經取代或經2個甲氧基所取代;η 是0或1,而R是氫或乙基。 -11 - 565455
特別有價值者是苯酯丙脯酸(enalapril),π奎那普利或啕 嗓納普利(indo lapril),其相對應之自由酸或其藥物上可接 受之酸加成鹽或驗性鹽。此型之化合物揭示於各美國專利 案第4,344,949; 4,3 74,829和4,425,3 55等中,以提及之方 式併入本文中。 成品組合物的總藥物含量可能是約1 %至約7 0 %,較佳自 約1 %至約2 5 %。而最佳係約5 %至約8 %。
除非在其他情況載明,本文中所述之所有百分數均係以 總組合物重量為基準之重量百分數。 本發明的藥物製劑之日需劑量以劑量形式的性質,藥物 的性質及藥物組合體中任何交互物之型式和範圍等為基 準。因此,個別病患所須要之治療和處方醫師之意願主宰 欲予採用之劑量級值。然而,就大體而論,任何藥物或藥 物組合體之製造商說明書是投藥之有用指導。可查閱醫生 之桌上參考資料或其他適當出版物而確定適當劑量級值。
雖然如此,p奎那普利和苯S旨丙脯酸之典型劑量級值係每 劑量自約1.毫克至約8 0毫克。 除去ACE抑制劑外,可採用於本發明組合物中之藥物的 適當分類可廣泛變更而通常代表任何安定之藥物聯合 體。舉例說明之分類和特定實例包括: (a) 利尿劑,例如氫氯苯屢璉; (b) 止咳劑,例如d-甲氧基_N-甲基嗎啡南,其氫溴化 物,1 - α -及可丁,維靜寧擰檬酸鹽和敵對咳氫氯化物, (c)抗組織胺劑,例如氯苯吡胺,馬來酸鹽,苯茚達明, -12- 565455 ⑻ 酒石酸鹽,吡拉明,馬來酸鹽,吡苯甲乙胺,琥珀酸鹽以 及苯基甲苯胺檸檬酸鹽, (d) 解除充血劑,例如苯基麻黃素,氫氯化物,苯基丙 醇胺氫氯化物,假麻黃素氫氯化物和麻黃素, (e) 各種植物驗,例如磷酸可待因,硫酸可待因,和嗎 啡, (f)礦物補充劑例如氯化鉀等。
欲使用於本文中之藥物及/或其他有益物質可選自各種 物質及其藥物上可接受形式,例如其酸類加成鹽。可使用 有機鹽類及無機鹽類假定藥物維持其藥物價值。例示之酸 性鹽包括(但並非受限為此)氫氯化物,氫澳化物,正磷酸 鹽,苯甲酸鹽,馬來酸鹽,酒石酸鹽,玻ίό酸鹽,檸檬酸 鹽,水楊酸鹽,硫酸鹽,乙酸鹽等。混合物亦可用。 欲與ACE抑制劑聯合而使用之較佳類別的藥物包括:冷 遮斷劑,利尿劑,#5遮斷劑等。
安定劑 經由某些上文所討論之藥物所顯示之環化和水解不安. 定性可經由使用適當數量,即··有效數量的氧化鎂連同將 A CE抑制劑之水解減至最小的化學劑,例如糖類而克服。 雖然附加之安定劑可存在於本發明中,但是與氧化鎂的安 定效果比較,其對於ACE抑制劑調配物之環化安定效果係 極小。當與存在於調配物中之氧化鎂的安定效果相比較 時,甚至少量的碳酸鎂(其可自暴露氧化鎂於水和空氣中 而產生)可具有對於ACE抑制劑調配物之最小安定效果。 -13 - 565455 應 或 鎂 案 明 膨 合 之 約 任 解 解 至 合 能 發 糖 抑 佳 (9) 氧化鎂或經煅燒之氧化鎂礦自下列公司商業上可供 :例如以色列的死海方鎂石公司;德國之Lohmann公司 摩爾頓(Morton)國際公司。此化合物天然產生係礦物方 石。自麥鎂礦礦苗,商業上製備氧化鎂記述於美國專利 第 3,320,029 中。 氧化鎂係以許多商業上等級而供應,所有等級均在本發 的範圍以内。兩種較佳形式的氧化鎂是稱為”輕質,,之極 鬆形式及稱為”重質”之稠密形式。 在本發明之較佳具體實施例中,經安定之ACE抑制劑組 物基本上係由作為環化安定劑之氧化鎂所組成。欲使用 氧化鎂的數量值於總組合物的約i %與9 〇 %間,约^ %至 5 0%較佳而以約1%至約1〇%最佳。就大體而論,可使用 何數量,其可有效阻礙或防止ACE抑制劑組份的環化降 水解減·至最少劑 本發明的水解減至最少劑充作保護ace抑制劑免於水 降解。欲予使用於本發明的藥物產物和方法中之水解減 最少劑是與氧化鎂可相容之物質以便彼等不敎干涉組 物中氧化鎂之功能。通常,彼等是各種物質其不含有可 顯著干涉含有金屬之組份或藥物組份的功能之基團。本 明的較佳之水解減至最少劑是糖類例如,甘露糖醇,乳
和其他糖,利尿劑,磷酸二鈣,氫氯噻噠及對於ACE 制劑具有將水解減至最少的功能之已知填料。以糖類最 而混合物可使用。
-14- 565455
(ίο) 通常,所存在之將水解減至最少劑的數量將是總組合物 的約1 0 %至約9 5 % ;較佳約5 0 %至約9 5 %而最佳係約7 0 %至 約 90%。 劑量形式
可將本發明的組合物單獨投藥給病患或作為含有其他 組份例如,賦形劑,稀釋劑和載體之其他組份的組合物一 部份,所有此等在該項技藝方面係眾所周知。此等組合物 可能以各種方式技藥予人類和動物例如口服,直腸内,腸 胃外方式(靜用c ,肌肉内或皮下),池内,陰道内,腹膜 内,膀胱内,局部式(粉末,油膏或滴劑)或作為頻部或鼻 部喷射。
依照本發明所造成之藥物製劑的最後形式可大為變 更。口服可投藥之形式,即:片劑,膜衣錠和膠囊較佳。 可造成固體,半固體和液體調配物。然而,以固體極佳。 可使用於本發明組合物中視情況選用之賦形劑亦是必須 與氧化鎂所相容之物質以使它不致干涉其在組合物中之 功能。 適合於腸胃外注射之組合物所包含藥理學上可接受之 滅菌水溶液或非水溶液,分散體,懸浮液或乳液及用以重 組入滅菌可注射之溶液或分散體中之滅菌粉末。適當之含 水和非水載體,稀釋劑,溶劑或載體的實例包括水,乙醇, 多元醇(丙二醇,聚乙二醇,甘油等)。Cremophor EL(黃 麻油和環氧乙烷的衍生物;購自MO州,聖路易市, S i g m a (西格馬化學公司)及其適當混合物,植物油(例如橄 -15- 565455
(ii) 欖油)及可注射之有機酯類例如油酸乙酯。適當之流度, 舉例而言,可經由使用一種塗料例如卵磷酯,經由維持所 需要之粒子大小(在分散體之情況)及經由使用界面活性 劑予以維持。
此等組合物亦可含有輔料例如,防腐劑,澄潤劑,乳化 劑和分散劑。防止微生物的作用可經由各種抗細菌劑和抗 黴菌劑予以保證,例如對氧苯甲酸酯,氯丁醇,酚,水梨 酸等。可能亦需要包括等滲壓劑,例如糖,氯化鈉等。可 注射之藥物形式的延長吸收所經由使用遲緩吸收劑而予 實現,舉例而言,單硬脂酸鋁和明膠。
適合口服投藥之固體劑量形式包括膠囊,片劑,丸劑, 粉末和顆粒。在此等固體劑量形式中,將活性化合物與至 少一種惰性慣用賦形劑(或載體)摻合,例如檸檬酸鈉或磷 酸二鈣或(a)填料或增充劑例如澱粉,乳糖,蔗糖,葡萄 糖,甘露糖醇和矽酸;(b)黏合劑例如段甲基纖維素,海 藻酸鹽,明膠,聚乙烯基吡咯烷酮,蔗糖和金含歡;(c) 保渔劑,例如甘油;(d)粉碎劑,例如瓊脂,馬玲薯或樹 薯澱粉,海藻酸,某些複合矽酸鹽,改質之澱粉,聚乙烯 基吡咯烷酮(交聯或未交聯)和改質之纖維素衍生物;(e) 溶液阻滯劑,例如石壤;(f)吸收加速劑,例如第四铵化 合物;(g)潤溼劑,例如鯨蠟醇和甘油單硬脂酸酯;(h)吸 附劑,例如高嶺土和膨潤土;(i)潤滑劑,例如滑石,氫 化之植物油,硬脂酸鋅,硬脂酸鈣,硬脂酸鎂,固體聚乙 二醇,月桂基硫酸鈉;(j)顏料;及(k)著色劑或其混合物。 -16- 565455 (12) 在膠囊,片劑和丸劑之情況下,劑量形式亦可包含緩衝劑。 亦可將相似型式的固體組合物採用於使用下列賦形劑 之軟和硬充填之明膠膠囊中作為填料:例如乳糖或乳糖以 及高分子量聚乙二醇等。
固體劑量形式例如片劑,糖衣丸,膠囊,丸劑和顆粒可 使用塗層和外殼予以製備,例如腸衣塗層和該項技藝中所 眾周知之其他者。彼等可含有遮光劑且亦可能是屬於此種 組合物,即··彼等以延遲方式在某一部份的腸道中放釋活 性化合物。可使用之嵌入組合物的實例是聚合物質和石 蠟。各種活性化合物亦可能係微包膠之形式,如果適當, 具有一種或多種的上述賦形劑。
適合口服投藥之液體劑量形式包括藥物上可接受之乳 液,溶液,懸浮液,糖漿和馳劑。除去活性化合物外,液 體劑量形式可含有該項技藝中通常所使用之惰性稀釋 劑,例如水或其他溶劑,增溶劑和乳化劑,例如乙醇,異 丙醇,碳酸乙酯,乙酸乙酯,芊醇,苯甲酸芊酯,丙二醇, 1,3 - 丁二醇,二甲基甲醯胺,油類(尤其棉子油,花生油, 玉米胚芽油,橄欖油,蔑麻油和芝麻油),甘油,四氫糠 醇,C r e m 〇 p h 〇 r E L (蔑麻油與環氧乙:):完的衍生物;購自Μ 0 州,聖路易市,Sigma化學公司),聚乙二醇和花楸糖醇酐 之脂肪酸醋或此等物質之混合物等。 除去此等惰性稀釋劑外,該組合物亦可包括輔料例如潤 澄劑,乳化和懸浮劑,增甜劑,香味劑和香料。除去活性 化合物外,懸浮液可含有懸浮劑,例如,經乙氧基化之異 -17- 565455
硬脂基醇,聚氧化乙烯花楸糖醇和花楸糖醇酐酯,微晶纖 維素,m-氫氧化鋁,膨潤土,瓊脂和黃蓍膠或此等物質 之混合物等。 適合直腸投藥之組合物較佳是坐藥,其可經由將本發明 化合物與適當無刺激性賦形劑混合予以製備例如,椰子 油,聚乙二醇或坐藥蠟,其在常溫下係固體但在體溫下係 液體而因此之故,在直腸或陰道穴中熔化而放釋活性組
份。 適合將本發明的組合物局部投藥之劑量形式包括油 膏,粉末,噴劑和吸入劑。將活性組份在滅菌條件下與一 種藥理學上可接受之載體摻合及視可能需要,與任何防腐 劑,緩衝劑或推進劑摻合。眼科配方,眼用油膏粉末和溶 液亦均考慮係屬於本發明的範圍以内。
可將上文中所特舉出之含有上述A CE抑制劑之組合物 以治療數量而使用,如醫生之桌上參考資料(PDR)第47版 Π 993 ) t所指示,以提及之方式併入本文中,或此等治療 有效數量如普通精於該項技藝之人士應知道者。 此等組合物可能以所建議之最大臨床劑量或以較低劑 量而投藥。本發明組合物中,活性化合物的劑量級值可變 更以便以投藥之途徑,疾病之嚴重性和病患之反應等為基 準而獲得所需要之治療回應。對於一特別病患,最適宜劑 量之決定係精於該項技藝人士所周知。 處理 本發明係關於用以安定ACE抑制齊f藥物之方法,此方法 -18- 565455
(14)
包括使有效數量的藥物與有效數量的氧化鎂和適含於阻 滯環化,水解及/或褪色之將水解減至最少劑接觸之步 驟,其中氧化鎂是組合物主要環化安定劑組份。雖然可採 用使藥物與氧化鎂接觸而為精於該項技藝人士所熟知之 任何技術(其係適當),但是以溼成粒方法較佳。氧化鎂的 存在對於含有ACE抑制劑之組合物的改良式溼成粒處理 有用,其優點在下列實例5中予以詳細討論,於該種情況 下,進行比較先前所熟知之碳酸氫氧化鎂調配物與本發明 之氧化鎂調配物。此等優點综合如下: (1)氧化鎂調配物係稠密且所容許使用目前設備而增加 分批大小; (2 )減少成粒時間,成粒時間範圍自約4 · 5至約5分鐘或 更短; (3) 減少成粒時間之變更性,當使用不同批的氧化鎂 時,變更性範圍自約〇 · 5至約1分鐘;
(4) 減少為獲得成粒終點所需要之水的數量並潛在性縮 短乾燥時間,所需要之水的數量是約50%或更少而乾燥時 間是約7分鐘; (5) 起始LOD係在5至8%之範圍内; (6) 當氧化鎂調配物具有320的流動性或休止用時,改良 流動性或休止用試驗。 在較佳具體實施例中,本發明係關於製備安定化之藥物 組合物之方法,此組合物包括有效數量之ACE抑制劑和將 水解減至最少劑且基本上係由作為環化安定劑之有效數 -19- (15) (15)565455 量的氧化鎂所組成,其中該方法包括: (1) 將適當數量的ACE抑制劑,將水 化鎂摻合在一起; 之取:> 劑和氧 (2) 添加成粒之流體至摻合物中而形成溼物料; (3) 乾燥顆粒;及 ’ (4) 將顆粒與藥物上鈍性之賦形劑摻合。 本万法另外包括在添加藥物上鈍性賦形 之顆粒的視情況選用步驟。然後可使如此所:乾M 物歷經另外習用之虛珂 ,.^ /成 < 成粒藥 將固體劑量形式經由習用技術處理成為 上:可 使用賦形劑之百分數並不重[通常,其數式。 藥物和安定劑组份在上文中所示一致::與關於 組合物的約1%至約15q/ 致(粉碎劑係總 …至、·,勺15%;潤滑劑係總組合 約5%^黏合劑係組合物的約 、·、,·1%至 足其餘的組合物。 41〇/°),即:彼等補 藥物製劑可能適合於立即,緩慢或持 此寺杈式的任何聯合體。因此, +挺式,或 分鐘内,產生起始自载劑量接著持:-、種碉配物適合於3C 12小時。以持續和立即放釋調配物· &釋其餘藥物歷4至 如有技巧之技師可能作 X佳。合理之變更,例 本文中作成。 ,、要不脫離本發明之範園可 ^列所陳述之實例意欲舉例說 把例而並無意欲以任何 Λ月《特殊具體實 的範圍。 ’、限制說明書或申請專利範圍 -20- 565455 (16) 實例1 將下列物料經由溼成粒方法處理以便製造2 0毫克片劑。 喹那普利氫氯化物 21.7毫克 氧化鎂 21.7毫克 乳糖 254.3毫克 明膠 6.4毫克 Polyplasdone 12.8毫克 硬脂酸鎂 3.2毫克
實例2 不添加安定劑,將下列物料經由溼成粒方法處理以便製 造5毫克片劑。 喹那普利氫氯化物 5.425克 無水,乳糖 1 1 9.5 7 5 克 微晶纖維素 1 4.775 克 二鈉 EDTA 0.225 克 Sterotex HM 1 .5 00 克 Syloid 244 矽膠 3 · 0 0 0 克 硬脂酸 4.500 t 抗壞血酸 U S P 1 ·000 克 水,純化U S P 2·25 0 克 實例3
不添加本發明之安定劑,將下列物料經由溼成粒方法處 理以便製造2 0毫克片劑。 -21 - 565455 (17) 喹那普利氫氯化物 21.7亳克 碳酸氫氧化鎂 125.0毫克 乳糖 33.3毫克 明膠 10.0毫克 Polyplasdone 8.0毫克 硬脂酸鎂 2.0毫克 實例4 在 6 0°C 下 ,試驗實例1至3中所製 備之片劑.的 安定 性 歷 10 天 〇 數據 顯 示:當對著不含安定彳 削之相似調! S物(實 例 2) 或 含 有碳 酸 氫氧化鎂之相似調配! 物(實例1 )比 較時 5 使 用 氧 化 鎂有 效 安定了含有A C E抑制劑組合物例如 ,口奎 那 普 利 H C 1組合物 。該數據不僅顯示:氧 化鎂安定了 含有 ACE抑 制 劑 之組 合 物以及碳酸氫氧化鎮, 而且氧化鎂 調配 物 較 碳 酸 氫 氧化 鎂 調配物(約5%)需要較 少之明膠(約 2%) 而 獲 得 可 接 受之 壓 縮性。 喹那普利(%) 產物之降解(%) 起始/1 0天 二酮基喊唤 水 解 產 物 實 例 1 98.7/98.9 -- 實 例 2a,b 68.1 32.4 < 1 實 例 3 97.7/96.1 -- - -22- 1 係源來喹那普利含量的百分數 b分析係在60 °c下,1個月後進行。 實例5 製備含有氧化鎂之喹那普利調配物及含有碳酸氫氧化 565455 (18) 鎂之喹那普利調配物以便在溼成粒處理中比較。各種調配 物(1.5仟克MgO和1.5仟克MgCO3)係經由聯合下列成份予 以製備·· 喹那普利H C 1 162.5 克 101.7 克 氧化鎂 -- 101.7克 碳酸鎂 93 7.5 克 -- 乳糖 250.0 克 1 191.6克 明膠 75.0 克 3 0 · 0 克 Polyplasdone 60.0 克 60.0 克 硬脂酸鎂 15.0 克 15.0 克 結果 • 氧化鎂調配物較碳酸氫氧化鎂調配物較為稠密。當與 1 . 5仟克之碳酸氫氧化鎂調配物比較時,2.5仟克之氧 化鎮調配物能在1 〇 L G r a 1中予以成粒。在添加明膠溶 液前,摻合物的鬆密度是0.70 g/mL(喹那普利/氧化鎂) 及0.27 g/mL〇奎那普利/碳酸氫氧化鎂)。 • 與碳酸氫氧化鎂調配物相比較(1 5至3 7分鐘),使用氧 化鎂調配物,成粒時間較短(4.5至5分鐘)。 • 減少成粒時間之變更性;使用不同批的碳酸氫氧化 鎂,大約1 5至1 7分鐘而使用不同批的氧化鎂只0 · 5至1 分鐘。 • 減少了為獲得成粒終點所使用之水的數量;氧化鎂較 碳酸氫氧化鎂調配物使用少5 0 %水。 • 氧化鎂調配物之起始LOD係在5%至8%範圍内,與碳酸 -23- 565455 (19) 氫氧化鎂調配物者,23 %至29%相比較。 • 氧化鎂:調配物較碳酸氫氧化鎂調配物之乾燥時間(1 5 至18分鐘)乾燥較快(7分鐘)。 • 在氧化鎂調配物中,避免二次溼研磨步騾因為未具有 與水份所形成之團塊在其中,與碳酸氫氧化鎂調配物 不同。 • 流動性或休止角試驗指示:氧化鎂調配物較碳酸氫氧
化鎂調配物(35 ^休止角)具有較佳之流動性(32^休止 角)。 • 與以5/10毫克和20/40毫克強度輸出喹那普利 HC1所 需要之兩種調配物比較,僅須一種含有氧化鎮之調配 物而能以四種強度(5,10,20與40毫克)輸出或製造喹 那普利HC1。
-24-
Claims (1)
- 565455 要安定劑,及 (b) —種或數種糖類, 其中該4那普利藥物係喹那普利或其藥物上可接受 之酸類加成鹽。 KX 如申請專利範圍第9項之方法,其中該方法另外包括 下列步驟: 將適當數量的喹那普利或其藥物上可接受之酸類加 成鹽,一種將水解減至最少劑和氧化鍰摻合在一起; 添加成粒之流體至摻合物中而形成溼物料; 乾燥顆粒;及 將顆粒與醫藥上鈍性之賦形劑摻合。 11.如申請專利範圍第1 〇項之方法,其中該方法另外包括 下列步驟: 在添加藥物上鈍性之賦形劑前,篩選經乾燥之顆粒 一次0 O:\58\58277-920922.DOQ Ί ::2 發明專利說明書 565455 中文說明書替換頁(92年9月) (填寫本書件時請先行詳閱申請書後之申請須知,作※記號部分請勿填寫) ※申請案號:088108107_糾PC分類: ※申請曰期: … 壹、 發明名稱 (中文)包含氧化鎂之含喳那普利(QUINAPRIL)之醫藥組合物,含其之錠 劑及安定喳那普利藥物之方法 (英文)QUINAPRIL-CONTAINING PHARMACEUTICAL COMPOSITION COMPRISING MAGNESIUM OXIDE, TABLET COMPRISING THE SAME AND PROCESS FOR STABILIZING A QUINAPRIL DRUG 貳、 發明人(共4人) 發明人J_ J如發明人超過一人,請填說明書發明人續頁) 姓名:(中文)真愛倫單尼 (英文)JANE ELLEN DANIEL 住居所地址:(中文)美國紐及塞州維洛納市克拉雷吉路1號 (英文) 國籍:(中文)美國 (英文)U.S.A· 參、申請人(共J_A) 申請人 1 (如申請人超過一人,請填說明書申請人續頁) 姓名或名稱:(中文) (英文) 住居所或營業所地址: 國籍:(中文)美國 代表人:(中文)羅斯· 美商華納蘭茂公司 WARNER-LAMBERT COMPANY (中文)美國紐及塞州摩理士白蘭市德卜路2〇1號 (英文) (英文)U.S.A. 阿姆斯壯 (英文)ROSE ARMSTRONG O:\58\58277-920922.DOC\ 1 565455 第088108107號專利申請案广- r - .................— 中文說明書替換頁(92年9月〇 ,.γ L丨卜 ,_ ‘一 拾、申請專利範圍 ^ Η ί J 1. 一種增進安定之醫藥組合物,其含有: (a) —種藥物組份,其包含適當數量的喹那普利 (quinapril)或其醫藥上可接受之酸類加成鹽,其易 感受環化,水解和褪色, (b) 適當數量的氧化鎂來阻滯環化和褪色,及 (c) 適當數量的水解減至最少劑來抑制水解。 2. 如申請專利範圍第1項之組合物,其中(a)含有至少一 種另外之藥物。 3. 如申請專利範圍第1項之組合物,其中氧化鎂是存在 於組合物中之唯一驗金屬鹽類。 4. 如申請專利範圍第1項之組合物,其中(b)含有每總重 量的調配物,約1 %至約9 0 %氧化鎂。 5. 如申請專利範圍第1項之組合物,其中(c)含有甘露糖 醇和乳糖之至少一種。 6. 如申請專利範圍第1項之組合物,其中該組合物亦含 有由下列各物中選出之至少一種物料:黏合劑,粉碎 劑和潤滑劑。 7. 如申請專利範圍第1項之組合物,其中水解減至最少 劑是一種糖類。 8. 一種錠劑,其包含如申請專利範圍第1項之組合物。 9. 一種用以安定喹那普利藥物對抗環化之方法,此方法 包括使藥物與下列兩項接觸的步驟: (a)適當數量的氧化鎂來阻滯環化,其中氧化鎂是主 O:\58\58277-920922.DOC\ 7
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8828098P | 1998-06-05 | 1998-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW565455B true TW565455B (en) | 2003-12-11 |
Family
ID=22210458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088108107A TW565455B (en) | 1998-06-05 | 1999-05-18 | Quinapril-containing pharmaceutical composition comprising magnesium oxide, tablet comprising the same and process for stabilizing a quinapril drug |
Country Status (32)
Country | Link |
---|---|
US (3) | US6417196B1 (zh) |
EP (1) | EP1083931B1 (zh) |
JP (1) | JP3727848B2 (zh) |
KR (1) | KR20010052557A (zh) |
CN (1) | CN1144598C (zh) |
AR (1) | AR019150A1 (zh) |
AT (1) | ATE295184T1 (zh) |
AU (1) | AU755616B2 (zh) |
BR (1) | BR9910947A (zh) |
CA (1) | CA2330581A1 (zh) |
CO (1) | CO5011043A1 (zh) |
DE (1) | DE69925269T2 (zh) |
ES (1) | ES2242398T3 (zh) |
GT (1) | GT199900079A (zh) |
HK (1) | HK1038879B (zh) |
HN (1) | HN1999000088A (zh) |
HU (1) | HUP0102260A3 (zh) |
ID (1) | ID27398A (zh) |
IL (1) | IL139590A0 (zh) |
IS (1) | IS2270B (zh) |
MY (1) | MY119667A (zh) |
NO (1) | NO20006148D0 (zh) |
NZ (1) | NZ508544A (zh) |
PA (1) | PA8475001A1 (zh) |
PE (1) | PE20000543A1 (zh) |
PL (1) | PL344586A1 (zh) |
SV (1) | SV1999000072A (zh) |
TR (1) | TR200003600T2 (zh) |
TW (1) | TW565455B (zh) |
UY (1) | UY25546A1 (zh) |
WO (1) | WO1999062560A1 (zh) |
ZA (1) | ZA200006537B (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69925269T2 (de) * | 1998-06-05 | 2006-02-23 | Warner-Lambert Co. Llc | Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid |
NZ333206A (en) | 1998-12-08 | 2000-07-28 | Bernard Charles Sherman | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
EP1300160B1 (en) * | 2000-05-24 | 2014-03-12 | Otsuka Pharmaceutical Co., Ltd. | Method of stabilizing preparation |
AU2003235579A1 (en) * | 2002-01-15 | 2003-07-30 | Delta Hf. | Formulations of quinapril and related ace inhibitors |
US20030157165A1 (en) * | 2002-02-01 | 2003-08-21 | Sherman Bernard Charles | Stable saccharide-free tablets comprising a salt of quinapril or moexipril |
US7638138B2 (en) * | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
CA2519287A1 (en) | 2003-03-27 | 2004-10-14 | Bioactis Limited | Powder medicine applicator for nasal cavity |
CZ298224B6 (cs) * | 2003-04-29 | 2007-07-25 | Pliva Istrazivanje I Razvoj D.O.O. | Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby |
DK1635792T3 (da) * | 2003-06-26 | 2009-06-15 | Teva Pharma | Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater |
US8673360B2 (en) * | 2004-08-10 | 2014-03-18 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions that enable rapid-acting and highly absorptive intranasal administration |
US20060141054A1 (en) | 2004-10-25 | 2006-06-29 | Thomas Piccariello | Metal coordinated compositions |
US7799937B2 (en) | 2004-10-25 | 2010-09-21 | Synthonics, Inc. | Metal coordinated compositions |
US8779175B2 (en) | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
ITMI20060026A1 (it) * | 2006-01-10 | 2007-07-11 | Truffini & Regge Farmaceutici Srl | Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento |
EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
US20070232680A1 (en) * | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
WO2007120930A2 (en) * | 2006-04-19 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
EP2034966A1 (en) * | 2006-06-30 | 2009-03-18 | Alphapharm Pty Ltd. | A stabilised composition comprising ace inhibitors |
US20080071141A1 (en) * | 2006-09-18 | 2008-03-20 | Abhisuek Gattani | Method and apparatus for measuring attributes of an anatomical feature during a medical procedure |
US8337817B2 (en) | 2006-12-26 | 2012-12-25 | Shin Nippon Biomedical Laboratories, Ltd. | Preparation for transnasal application |
WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
JP5113476B2 (ja) * | 2007-10-09 | 2013-01-09 | 沢井製薬株式会社 | 保存安定性に優れた塩酸テモカプリルの錠剤 |
US9101539B2 (en) * | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
US8827946B2 (en) | 2009-07-31 | 2014-09-09 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
TR200906322A2 (tr) | 2009-08-17 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Çözünürlük ve stabilite özellikleri geliştirilmiş granüller. |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
CN102512656B (zh) * | 2011-12-27 | 2013-11-27 | 天津市嵩锐医药科技有限公司 | 盐酸喹那普利药物组合物 |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320029A (en) * | 1967-05-16 | Method of preparing magnesia | ||
IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
US4425355A (en) * | 1981-02-17 | 1984-01-10 | Warner-Lambert Company | Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids |
US4830853A (en) * | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
US4793998A (en) * | 1986-10-20 | 1988-12-27 | Warner-Lambert Company | Stabilized drug compositions |
US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
US4830583A (en) * | 1988-03-02 | 1989-05-16 | Sri International | Fluid motor-pumping apparatus and system |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
HU222489B1 (hu) | 1990-07-25 | 2003-07-28 | Novartis Ag. | Stabilizált gyógyszerkészítmények és eljárás az előállításukra |
IT1251153B (it) * | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
DE69925269T2 (de) * | 1998-06-05 | 2006-02-23 | Warner-Lambert Co. Llc | Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid |
NZ333206A (en) * | 1998-12-08 | 2000-07-28 | Bernard Charles Sherman | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor |
-
1999
- 1999-05-10 DE DE69925269T patent/DE69925269T2/de not_active Revoked
- 1999-05-10 AT AT99922899T patent/ATE295184T1/de not_active IP Right Cessation
- 1999-05-10 BR BR9910947-6A patent/BR9910947A/pt not_active Application Discontinuation
- 1999-05-10 ID IDW20002515A patent/ID27398A/id unknown
- 1999-05-10 CN CNB998070262A patent/CN1144598C/zh not_active Expired - Fee Related
- 1999-05-10 US US09/700,883 patent/US6417196B1/en not_active Expired - Fee Related
- 1999-05-10 IL IL13959099A patent/IL139590A0/xx not_active IP Right Cessation
- 1999-05-10 EP EP99922899A patent/EP1083931B1/en not_active Revoked
- 1999-05-10 CA CA002330581A patent/CA2330581A1/en not_active Abandoned
- 1999-05-10 AU AU39793/99A patent/AU755616B2/en not_active Ceased
- 1999-05-10 HU HU0102260A patent/HUP0102260A3/hu unknown
- 1999-05-10 WO PCT/US1999/010189 patent/WO1999062560A1/en active IP Right Grant
- 1999-05-10 PL PL99344586A patent/PL344586A1/xx not_active Application Discontinuation
- 1999-05-10 JP JP2000551814A patent/JP3727848B2/ja not_active Expired - Fee Related
- 1999-05-10 ES ES99922899T patent/ES2242398T3/es not_active Expired - Lifetime
- 1999-05-10 NZ NZ508544A patent/NZ508544A/xx unknown
- 1999-05-10 KR KR1020007013714A patent/KR20010052557A/ko not_active Application Discontinuation
- 1999-05-10 TR TR2000/03600T patent/TR200003600T2/xx unknown
- 1999-05-18 TW TW088108107A patent/TW565455B/zh not_active IP Right Cessation
- 1999-06-03 HN HN1999000088A patent/HN1999000088A/es unknown
- 1999-06-03 MY MYPI99002229A patent/MY119667A/en unknown
- 1999-06-04 PA PA19998475001A patent/PA8475001A1/es unknown
- 1999-06-04 CO CO99035274A patent/CO5011043A1/es unknown
- 1999-06-04 SV SV1999000072A patent/SV1999000072A/es not_active Application Discontinuation
- 1999-06-04 AR ARP990102642A patent/AR019150A1/es not_active Application Discontinuation
- 1999-06-04 PE PE1999000475A patent/PE20000543A1/es not_active Application Discontinuation
- 1999-06-04 GT GT199900079A patent/GT199900079A/es unknown
- 1999-06-04 UY UY25546A patent/UY25546A1/es not_active IP Right Cessation
-
2000
- 2000-11-10 IS IS5712A patent/IS2270B/is unknown
- 2000-11-10 ZA ZA200006537A patent/ZA200006537B/en unknown
- 2000-12-04 NO NO20006148A patent/NO20006148D0/no unknown
-
2002
- 2002-01-18 HK HK02100407.5A patent/HK1038879B/zh not_active IP Right Cessation
- 2002-04-22 US US10/127,181 patent/US7015232B2/en not_active Expired - Fee Related
-
2005
- 2005-12-15 US US11/313,123 patent/US20060106057A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW565455B (en) | Quinapril-containing pharmaceutical composition comprising magnesium oxide, tablet comprising the same and process for stabilizing a quinapril drug | |
CA1300510C (en) | Stabilized composition containing angiotensin converting enzyme | |
US8383150B2 (en) | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients | |
JP2002500233A (ja) | 抗−クリプトコッカルペプチド類 | |
KR100922519B1 (ko) | 펠루비프로펜을 함유하는 용출률 및 안정성이 개선된 경구투여용 약제학적 제제 | |
US20210069192A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
WO2003009805A2 (en) | Analgesic methods using endothelin receptor ligands | |
KR20060127875A (ko) | 아로마타제 억제제 요법-관련된 골다공증의 치료 | |
CA2780332A1 (en) | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea | |
US20090163544A1 (en) | Use of NK-3 Receptor Antagonists for the Treatment of Nausea and Vomiting | |
JP2847866B2 (ja) | 消化性潰瘍治療剤 | |
JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
EP0563697B1 (en) | Cytarabine ocfosfate hard capsule | |
JP2776837B2 (ja) | 消化性潰瘍治療剤 | |
CA2410589A1 (en) | Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine | |
JPH08325142A (ja) | ヨウ化イソプロパミド含有製剤 | |
JP2006076956A (ja) | 胃炎の治療・予防用配合剤 | |
JPS60202812A (ja) | ブロモクリプチン組成物 | |
KR0184350B1 (ko) | 오메프라졸 구강점막 부착 정제 조성물 | |
MXPA00011299A (en) | Stabilization of compositions containing ace inhibitors using magnesium oxide | |
KR950005869B1 (ko) | 위염 치료제 | |
JPS63166836A (ja) | シクロオキシゲナ−ゼ阻害活性物質を含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |